Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 2/2008

01-02-2008 | Original Article

Control of lymphocyte infiltration of lung tumors in mice by host’s genes: mapping of four Lynf (lymphocyte infiltration) loci

Authors: Neelima Kakarlapudi, Juanita H. J. Vernooy, Lei Quan, Remond J. A. Fijneman, Peter Demant

Published in: Cancer Immunology, Immunotherapy | Issue 2/2008

Login to get access

Abstract

Tumor infiltration by lymphocytes is essential for cell-mediated immune elimination of tumors in experimental systems and in immunotherapy of cancer. Presence of lymphocytes in several human cancers has been associated with a better prognosis. We present evidence that individual propensity to tumor infiltration is genetically controlled. Infiltrating lymphocytes are present in 50% of lung tumors in O20/A mice, but in only 10% of lung tumors in OcB-9/Dem mice. This difference has been consistent in experiments conducted over 8 years in two different animal facilities. To test whether this strain difference is controlled genetically, we analyzed the presence of infiltrating lymphocytes in N-ethyl-N-nitroso-urea (ENU) induced lung tumors in (O20 × OcB-9) F2 hybrids. We mapped four genetic loci, Lynf1 (Lymphocyte infiltration 1), Lynf2, Lynf3, and Lynf4 that significantly modify the presence and intensity of intra-tumoral infiltrates containing CD4+ and CD8+ T lymphocytes. These loci appear to be distinct from the genes encoding the molecules that are presently implicated in lymphocyte infiltration. Our findings open a novel approach for the assessment of individual propensity for tumor infiltration by genotyping the genes of the host that influence this process using DNA from any normal tissue. Such prediction of probability of tumor infiltration in individual cancer patients could help considerably to assess their prognosis and to decide about the application and the type of immunotherapy.
Literature
1.
go back to reference Ochsenbein AF et al (2001) Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411:1058–1064PubMedCrossRef Ochsenbein AF et al (2001) Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411:1058–1064PubMedCrossRef
2.
go back to reference Wick M, Dubey P, Koeppen H, Siegel CT, Fields PE, Chen L, Bluestone JA, Schreiber H (1997) Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med 186:229–238PubMedCrossRef Wick M, Dubey P, Koeppen H, Siegel CT, Fields PE, Chen L, Bluestone JA, Schreiber H (1997) Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med 186:229–238PubMedCrossRef
3.
go back to reference Ganss R, Hanahan D (1998) Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res 58:4673–4681PubMed Ganss R, Hanahan D (1998) Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res 58:4673–4681PubMed
4.
go back to reference Ganss R, Limmer A, Sacher T, Arnold B, Hammerling GJ (1999) Autoaggression and tumor rejection: it takes more than self-specific T-cell activation. Immunol Rev 169:263–272PubMedCrossRef Ganss R, Limmer A, Sacher T, Arnold B, Hammerling GJ (1999) Autoaggression and tumor rejection: it takes more than self-specific T-cell activation. Immunol Rev 169:263–272PubMedCrossRef
5.
go back to reference Galon J et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964PubMedCrossRef Galon J et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964PubMedCrossRef
6.
go back to reference Diederichsen AC, Hjelmborg JB, Christensen PB, Zeuthen J, Fenger C (2003) Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother 52:423–428PubMedCrossRef Diederichsen AC, Hjelmborg JB, Christensen PB, Zeuthen J, Fenger C (2003) Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother 52:423–428PubMedCrossRef
7.
go back to reference Sato E et al (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102:18538–18543PubMedCrossRef Sato E et al (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102:18538–18543PubMedCrossRef
8.
go back to reference Clemente CG, Mihm MC Jr., Bufalino R, Zurrida S, Collini P, Cascinelli N (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77:1303–1310PubMedCrossRef Clemente CG, Mihm MC Jr., Bufalino R, Zurrida S, Collini P, Cascinelli N (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77:1303–1310PubMedCrossRef
9.
10.
go back to reference Chen Q, Wang WC, Evans SS (2003) Tumor microvasculature as a barrier to antitumor immunity. Cancer Immunol Immunother 52:670–679PubMedCrossRef Chen Q, Wang WC, Evans SS (2003) Tumor microvasculature as a barrier to antitumor immunity. Cancer Immunol Immunother 52:670–679PubMedCrossRef
11.
go back to reference Tripodis N, Demant P (2001) Genetic linkage of nuclear morphology of mouse lung tumors to the Kras-2 locus. Exp Lung Res 27:185–196PubMedCrossRef Tripodis N, Demant P (2001) Genetic linkage of nuclear morphology of mouse lung tumors to the Kras-2 locus. Exp Lung Res 27:185–196PubMedCrossRef
12.
go back to reference Horlings H, Demant P (2005) Lung tumor location and lymphocyte infiltration in mice are genetically determined. Exp Lung Res 31:513–525PubMedCrossRef Horlings H, Demant P (2005) Lung tumor location and lymphocyte infiltration in mice are genetically determined. Exp Lung Res 31:513–525PubMedCrossRef
13.
go back to reference Demant P, Hart AA (1986) Recombinant congenic strains—a new tool for analyzing genetic traits determined by more than one gene. Immunogenetics 24:416–422PubMedCrossRef Demant P, Hart AA (1986) Recombinant congenic strains—a new tool for analyzing genetic traits determined by more than one gene. Immunogenetics 24:416–422PubMedCrossRef
14.
go back to reference Stassen AP, Groot PC, Eppig JT, Demant P (1996) Genetic composition of the recombinant congenic strains. Mamm Genome 7:55–58PubMedCrossRef Stassen AP, Groot PC, Eppig JT, Demant P (1996) Genetic composition of the recombinant congenic strains. Mamm Genome 7:55–58PubMedCrossRef
15.
go back to reference Groot PC, Moen CJ, Dietrich W, Stoye JP, Lander ES, Demant P (1992) The recombinant congenic strains for analysis of multigenic traits: genetic composition. FASEB J 6:2826–2835PubMed Groot PC, Moen CJ, Dietrich W, Stoye JP, Lander ES, Demant P (1992) The recombinant congenic strains for analysis of multigenic traits: genetic composition. FASEB J 6:2826–2835PubMed
16.
go back to reference Fijneman RJ, de Vries SS, Jansen RC, Demant P (1996) Complex interactions of new quantitative trait loci, Sluc1, Sluc2, Sluc3, and Sluc4, that influence the susceptibility to lung cancer in the mouse. Nat Genet 14:465–467PubMedCrossRef Fijneman RJ, de Vries SS, Jansen RC, Demant P (1996) Complex interactions of new quantitative trait loci, Sluc1, Sluc2, Sluc3, and Sluc4, that influence the susceptibility to lung cancer in the mouse. Nat Genet 14:465–467PubMedCrossRef
17.
go back to reference Fijneman RJ, van der Valk MA, Demant P (1998) Genetics of quantitative and qualitative aspects of lung tumorigenesis in the mouse: multiple interacting Susceptibility to lung cancer (Sluc) genes with large effects. Exp Lung Res 24:419–436PubMed Fijneman RJ, van der Valk MA, Demant P (1998) Genetics of quantitative and qualitative aspects of lung tumorigenesis in the mouse: multiple interacting Susceptibility to lung cancer (Sluc) genes with large effects. Exp Lung Res 24:419–436PubMed
18.
go back to reference Tripodis N, Hart AA, Fijneman RJ, Demant P (2001) Complexity of lung cancer modifiers: mapping of thirty genes and twenty-five interactions in half of the mouse genome. J Natl Cancer Inst 93:1484–1491PubMedCrossRef Tripodis N, Hart AA, Fijneman RJ, Demant P (2001) Complexity of lung cancer modifiers: mapping of thirty genes and twenty-five interactions in half of the mouse genome. J Natl Cancer Inst 93:1484–1491PubMedCrossRef
19.
go back to reference Tripodis N, Demant P (2003) Genetic analysis of three-dimensional shape of mouse lung tumors reveals eight lung tumor shape-determining (Ltsd) loci that are associated with tumor heterogeneity and symmetry. Cancer Res 63:125–131PubMed Tripodis N, Demant P (2003) Genetic analysis of three-dimensional shape of mouse lung tumors reveals eight lung tumor shape-determining (Ltsd) loci that are associated with tumor heterogeneity and symmetry. Cancer Res 63:125–131PubMed
20.
go back to reference Vernooy JH, Dentener MA, van Suylen RJ, Buurman WA, Wouters EF (2002) Long-term intratracheal lipopolysaccharide exposure in mice results in chronic lung inflammation and persistent pathology. Am J Respir Cell Mol Biol 26:152–159PubMed Vernooy JH, Dentener MA, van Suylen RJ, Buurman WA, Wouters EF (2002) Long-term intratracheal lipopolysaccharide exposure in mice results in chronic lung inflammation and persistent pathology. Am J Respir Cell Mol Biol 26:152–159PubMed
21.
go back to reference NormanGR, StreinerDL (2000) Biostatistics, 2nd edn. BCDecker, Hamilton, p 265 NormanGR, StreinerDL (2000) Biostatistics, 2nd edn. BCDecker, Hamilton, p 265
22.
go back to reference Lander E, Kruglyak L (1995) Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet 11:241–247PubMedCrossRef Lander E, Kruglyak L (1995) Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet 11:241–247PubMedCrossRef
23.
go back to reference Fijneman RJ, Vos M, Berkhof J, Demant P, Kraal G (2004) Genetic analysis of macrophage characteristics as a tool to identify tumor susceptibility genes: mapping of three macrophage-associated risk inflammatory factors, marif1, marif2, and marif3. Cancer Res 64:3458–3464PubMedCrossRef Fijneman RJ, Vos M, Berkhof J, Demant P, Kraal G (2004) Genetic analysis of macrophage characteristics as a tool to identify tumor susceptibility genes: mapping of three macrophage-associated risk inflammatory factors, marif1, marif2, and marif3. Cancer Res 64:3458–3464PubMedCrossRef
24.
go back to reference Lipoldova M, Havelkova H, Badalova J, Demant P (2005) Novel loci controlling lymphocyte proliferative response to cytokines and their clustering with loci controlling autoimmune reactions, macrophage function and lung tumor susceptibility. Int J Cancer 114:394–399PubMedCrossRef Lipoldova M, Havelkova H, Badalova J, Demant P (2005) Novel loci controlling lymphocyte proliferative response to cytokines and their clustering with loci controlling autoimmune reactions, macrophage function and lung tumor susceptibility. Int J Cancer 114:394–399PubMedCrossRef
25.
go back to reference von Andrian UH, Mempel TR (2003) Homing and cellular traffic in lymph nodes. Nat Rev Immunol 3:867–878CrossRef von Andrian UH, Mempel TR (2003) Homing and cellular traffic in lymph nodes. Nat Rev Immunol 3:867–878CrossRef
27.
go back to reference de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6:24–37PubMedCrossRef de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6:24–37PubMedCrossRef
28.
go back to reference Sinha P, Clements VK, Miller S, Ostrand-Rosenberg S (2005) Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol Immunother 54:1137– 1142PubMedCrossRef Sinha P, Clements VK, Miller S, Ostrand-Rosenberg S (2005) Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol Immunother 54:1137– 1142PubMedCrossRef
29.
go back to reference Baecher-Allan C, Anderson DE (2006) Immune regulation in tumor-bearing hosts. Curr Opin Immunol 18:214–219PubMedCrossRef Baecher-Allan C, Anderson DE (2006) Immune regulation in tumor-bearing hosts. Curr Opin Immunol 18:214–219PubMedCrossRef
30.
go back to reference Yamaguchi T, Sakaguchi S (2006) Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 16:115–123PubMedCrossRef Yamaguchi T, Sakaguchi S (2006) Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 16:115–123PubMedCrossRef
31.
go back to reference Ostrand-Rosenberg S (2005) CD4+ T lymphocytes: a critical component of antitumor immunity. Cancer Invest 23:413–419PubMed Ostrand-Rosenberg S (2005) CD4+ T lymphocytes: a critical component of antitumor immunity. Cancer Invest 23:413–419PubMed
32.
go back to reference Colombo MP, Mantovani A (2005) Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. Cancer Res 65:9113–9116PubMedCrossRef Colombo MP, Mantovani A (2005) Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. Cancer Res 65:9113–9116PubMedCrossRef
Metadata
Title
Control of lymphocyte infiltration of lung tumors in mice by host’s genes: mapping of four Lynf (lymphocyte infiltration) loci
Authors
Neelima Kakarlapudi
Juanita H. J. Vernooy
Lei Quan
Remond J. A. Fijneman
Peter Demant
Publication date
01-02-2008
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 2/2008
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-007-0367-3

Other articles of this Issue 2/2008

Cancer Immunology, Immunotherapy 2/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine